Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
---|
08/30/2001 | WO2001062223A2 Cosmetic preparations containing plant extracts |
08/30/2001 | WO2001062214A1 Gelled aqueous cosmetic compositions |
08/30/2001 | WO2001062213A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same |
08/30/2001 | WO2001062082A2 Use of phenylethylamine derivatives for the anitmicrobial treatment of surfaces |
08/30/2001 | WO2001024842A3 Hybrid matrices and hybrid matrix mixtures |
08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
08/30/2001 | WO2001010430A3 Use of estrogen compounds for prevention and treatment of ischemic damage |
08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
08/30/2001 | US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
08/30/2001 | US20010018451 Raloxifene, tamoxifen |
08/30/2001 | US20010018449 Hypotensive agent, endothelial damage, arteriosclerosis, antidiabetic agents |
08/30/2001 | US20010018447 Il-8 receptor antagonists |
08/30/2001 | US20010018432 Skin disorders; acne, seborrhea |
08/30/2001 | US20010018430 Anticancer agents, psoriasis, restenosis, atherosclerosis |
08/30/2001 | US20010018418 Method of promoting angiogenesis |
08/30/2001 | US20010018068 Water insoluble substrate comprising creped nonwoven layer and cleansing component (lathering surfactant); cleaning/ conditioning skin/hair; disposable; materials handling |
08/30/2001 | US20010018062 Single-phase transparent aqueous cosmetic composition |
08/30/2001 | US20010018060 Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
08/30/2001 | CA2406871A1 Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
08/30/2001 | CA2401113A1 Transporters and ion channels |
08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
08/30/2001 | CA2401036A1 Pyridinylimidazoles |
08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
08/30/2001 | CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
08/30/2001 | CA2400923A1 Tyrosine kinase inhibitors |
08/30/2001 | CA2400892A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same |
08/30/2001 | CA2400875A1 Tyrosine kinase inhibitors |
08/30/2001 | CA2400694A1 Thiazolium compounds and treatments of disorders associated with protein aging |
08/30/2001 | CA2400435A1 Novel compounds |
08/30/2001 | CA2400434A1 Novel compounds |
08/30/2001 | CA2400293A1 Novel compounds |
08/30/2001 | CA2400040A1 Integrin antagonists |
08/30/2001 | CA2399211A1 Foam-forming wound dressing |
08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
08/30/2001 | CA2368382A1 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
08/30/2001 | CA2368366A1 Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient |
08/30/2001 | CA2368364A1 A stable composition comprising epidermal growth factor as an active ingredient |
08/30/2001 | CA2365606A1 Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient |
08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
08/29/2001 | EP1127576A1 Uses of NM23-polypeptides in skin and intestinal disorders |
08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
08/29/2001 | EP1127121A2 Construction of retrovirus with the streptomyces mel locus expressible in mammalian cells |
08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
08/29/2001 | EP1127051A2 Tricyclic pyrazole derivatives |
08/29/2001 | EP1126868A2 Method of modulating hair growth |
08/29/2001 | EP1126863A1 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
08/29/2001 | EP1126861A2 Compositions comprising oleum melaleuca |
08/29/2001 | EP1126854A1 Benzoazepines and analogs thereof useful as growth hormone secretagogues |
08/29/2001 | EP1126852A1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
08/29/2001 | EP1126845A2 New use of immunosuppressants for mmp-mediated diseases |
08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
08/29/2001 | EP1126838A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
08/29/2001 | EP1126837A1 Fulvic acid and its use in the treatment of various conditions |
08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
08/29/2001 | EP1126812A1 Treatment of skin with adenosine or adenosine analog |
08/29/2001 | EP1000089A4 Collagen type i and type iii adhesive compositions |
08/29/2001 | EP0968168B1 Aromatic tetracyclic compounds of the retinoid type, method for preparing and use |
08/29/2001 | CN1310716A Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
08/29/2001 | CN1310708A Substituted phenylamidines with antithrombotic action |
08/29/2001 | CN1310627A Hair growth/maintenance compositions and methods involving the same |
08/29/2001 | CN1310624A Extraction method, pharmaceutical composition and a cosmetic composition |
08/29/2001 | CN1310621A Substituted anilide compounds and methods |
08/29/2001 | CN1310178A Alkylation process and new hydroxy-phenyl-benzotriazole compound |
08/29/2001 | CN1310175A Process for producing bis (4-amino-1-pyridine) paraffins |
08/29/2001 | CN1310021A Health giving and face nursing composition of natural material |
08/29/2001 | CN1309995A Medicine for treating burn, scald, frost bite and wound |
08/29/2001 | CN1309981A Carbuncle treating medicine powder |
08/29/2001 | CN1309972A Garter snake capsule |
08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
08/29/2001 | CN1309967A Acne treating skin care cream |
08/29/2001 | CN1309961A Preparation of natural antisenility skin care liquid |
08/29/2001 | CN1309960A Acne eliminating composition and its usage |
08/29/2001 | CN1309926A Preparation of additive for food, medicine and cosmetics and replenishing linolic acid and gamma-linolenic acid |
08/29/2001 | CN1070064C Method for preparing ointment for curing burns and scalds |
08/28/2001 | US6281241 Use of melatonin for the treatment of androgenetic alopecia |
08/28/2001 | US6281239 Tissue softening composition containing urea and an antifungal composition |
08/28/2001 | US6281236 Containing allantoin and an emulsifier has improved stability coming from the adjustment of the ph to a range of 4.5 to 5.8. |
08/28/2001 | US6281212 Chemokine receptor antagonists and methods of use therefor |
08/28/2001 | US6281210 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
08/28/2001 | US6281194 E.g., (s)-(1-((4-benzyloxy-benzyl)-(((1-phenyl-cyclobutylmethyl)-car bamoyl)-methyl)-carbamoyl)-2-(1h-imidazol-4-yl)-ethyl)-carbami c acid benzyl ester |
08/28/2001 | US6280971 Polynucleotide associated with detection of staphylococcus; for use in screening bactericides |
08/28/2001 | US6280953 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
08/28/2001 | US6280751 For treatment of disease or physical disability or sports injuries, for build up and maintenance of immune system, or for protection against disease or pollution |
08/28/2001 | US6280747 Cosmetic or dermatological composition contacting at least one natural or recombinant spider silk or an analog |
08/23/2001 | WO2001061017A2 Modified cytokines for use in cancer therapy |
08/23/2001 | WO2001061007A2 Fibroblast growth factor-23 molecules and uses thereof |
08/23/2001 | WO2001060922A1 Process for the preparation of micronised collagen, and its therapeutic applications |
08/23/2001 | WO2001060835A1 Purine derivatives |
08/23/2001 | WO2001060833A2 Motilide compounds |
08/23/2001 | WO2001060821A1 Novel biarylcarboxamides |
08/23/2001 | WO2001060816A1 Kinase inhibitors |
08/23/2001 | WO2001060814A2 Pyrrole substituted 2-indolinone protein kinase inhibitors |
08/23/2001 | WO2001060808A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
08/23/2001 | WO2001060807A1 Aryloxyacetic acids for diabetes and lipid disorders |
08/23/2001 | WO2001060784A1 Aniline-derived ligands for the thyroid receptor |
08/23/2001 | WO2001060778A2 Aspirin-triggered lipid mediators |